Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Park Ha Biological Technology CoBYAH -1.79%20 Equity-to-Asset is 0.72 as of Apr. 2026, which is 47% above its 10-year median of 0.49. GuruFocus rates BYAH with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 2,002 Consumer Packaged Goods companies, Park Ha Biological Technology Co ranks better than 76.02% on this metric.
The historical rank and industry rank for Park Ha Biological Technology Co's Equity-to-Asset or its related term are showing as below:
BYAH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.97 Med: 0.49 Max: 0.73
Current: 0.72
During the past 5 years, the highest Equity to Asset Ratio of Park Ha Biological Technology Co was 0.73. The lowest was -0.97. And the median was 0.49.
BYAH's Equity-to-Asset is ranked better than 76.02% of 2002
companies
in the Consumer Packaged Goods industry
Industry Median: 0.545
vs BYAH: 0.72
Park Ha Biological Technology Co (NAS:BYAH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Park Ha Biological Technology Co Equity-to-Asset Related Terms
Park Ha Biological Technology Co Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Park Ha Biological Technology Co Equity-to-Asset Chart
BYAH vs CAWW, NASO, SKVI: Equity-to-Asset Comparison
For the Household & Personal Products subindustry, Park Ha Biological Technology Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Park Ha Biological Technology Co Equity-to-Asset vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Park Ha Biological Technology Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Park Ha Biological Technology Co's Equity-to-Asset falls into.
Park Ha Biological Technology Co Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Park Ha Biological Technology Co (BYAH) has a Equity-to-Asset of 0.72 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Park Ha Biological Technology Co and its competitors. This is 47% above median its historical median of 0.49. According to the industry distribution chart, Park Ha Biological Technology Co ranks #480 out of 2002 companies in the Consumer Packaged Goods industry, placing it in the top 24%.
Is Park Ha Biological Technology Co's Equity-to-Asset too high?
Park Ha Biological Technology Co's current Equity-to-Asset of 0.72 is 47% above median its 10-year median of 0.49. The Consumer Packaged Goods industry median Equity-to-Asset is 0.55. Park Ha Biological Technology Co's value of 0.72 is 32.1% above this industry median. Based on the distribution chart, Park Ha Biological Technology Co ranks #480 out of 2002 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Park Ha Biological Technology Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Park Ha Biological Technology Co's Equity-to-Asset compare to CAWW and NASO?
According to the Consumer Packaged Goods industry distribution chart, Park Ha Biological Technology Co ranks #480 out of 2002 companies for Equity-to-Asset. This places Park Ha Biological Technology Co in the top 24% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.55. Park Ha Biological Technology Co's value of 0.72 is 32.1% above this benchmark. While the company's 10-year median is 0.49 vs. the industry median of 0.55, Park Ha Biological Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Consumer Packaged Goods company?
The median Equity-to-Asset among Consumer Packaged Goods companies is 0.55, based on 2,002 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Park Ha Biological Technology Co's current Equity-to-Asset of 0.72 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Park Ha Biological Technology Co and its competitors. For the Consumer Packaged Goods industry, the median Equity-to-Asset is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Park Ha Biological Technology Co's current Equity-to-Asset is 0.72, which is 47% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Park Ha Biological Technology Co stock overvalued right now?
Park Ha Biological Technology Co (BYAH) has a current Equity-to-Asset of 0.72. The current Equity-to-Asset is 0.72, which is 47% above median its 10-year median of 0.49 and 32.1% above the Consumer Packaged Goods industry median of 0.55. Park Ha Biological Technology Co's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Park Ha Biological Technology Co (BYAH), the current Equity-to-Asset is 0.72 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
20GF Score
Get the complete analysis for BYAH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BYAH has been successfully added to your 
